早期应用 G-CSF 联合地榆升白片干预升白治疗在肿瘤化疗中的效果分析

摘要

目的：观察早期应用 G - CSF 联合地榆升白片干预升白治疗在肿瘤化疗中的疗效及安全性。方法：120例恶性肿瘤患者随机分成两组各60例，治疗组在化疗的同时给予地榆升白片治疗，结合血常规，早期预防性应用粒细胞集落刺激因子（ G- CSF）升白治疗；对照组在化疗后出现Ⅱ度以上骨髓抑制才给予升白治疗，疗程6程。比较分析两组白细胞减少及生存质量情况。结果：治疗组化疗后出现白细胞减少12例（20％），Kps 评分下降8例（12.5％），提高50例（83.33％），56例（93.33％）按期完成化疗；对照组化疗后出现白细胞减少33例（55％），Kps 评分下降23例（38.33％），提高30例（50％），45例（75％）按期完成化疗，有2例因不良反应而中止化疗。两组比较差异有统计学意义（P ﹤0.05）。结论：血常规指导下早期应用 G - CSF 联合地榆升白片干预升白治疗能显著减少肿瘤化疗后白细胞减少，保障化疗进行，提高生存质量，未发生严重不良反应。%Objective To investigate the efficacy,safety and clinical significance of granulocyte Colony - stimulating Factor(G - CSF) and Diyushengbai table early - used on the tumor - chemotherapy. Method 120 patients with cancer were divided into two groups,60 ca-ses of each group. The therapy group received Diyushengbai table,early selectivity received G - CSF related to blood cell analysis(BCA)at chemotherapy period,The control group received G - CSF and Diyushengbai table at the gap period aboveⅡgroup Leucopenia,two groups for 6 doses. Analyze the efficacy,side effects,quality of life in two groups. Results The treatment group:Leucopenia 12 cases( 20% ),KPS score decreased 8 cases( 12. 5% ),raised 50 cases( 83. 33% ),56 cases( 93. 33% )finished chemotherapy on time;The control group:Leucopenia 33 cases( 55% ),KPS score decreased 23 cases( 38. 33% ),raised 30 cases( 50% ),45 cases(75% )finished chemotherapy on time,2 cases stopped chemotherapy due to adverse events. The difference was statistically significant(P ﹤ 0. 05). Conclusion G - CSF and Diyushengbai table early - used on the tumor - chemotherapy by the BCA has a certain effect,with a higher clinical benefit,low toxicity and good safety.